Jonathan M. Loree
Advanced in Pancreatic Islet Cell Tumor

Jonathan M. Loree

Vancouver, BC, CA 
Advanced in Pancreatic Islet Cell Tumor
Vancouver, BC, CA 
OverviewLocationsClinical Research

Overview

Jonathan Loree practices in Vancouver, Canada. Mr. Loree is rated as an Advanced expert by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 143 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Pancreatic Islet Cell Tumor.

Gender
Male

Locations

Vancouver, BC, Canada
Other Locations
600 West 10th Avenue, BC V5Z4E6, Canada
Ottawa, ON K1E3R9, Canada
11560 University Avenue, Edmonton, AB T6G1Z2, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Lutathera, Octreotide
Study Phase: Phase 3
An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX
An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX
Enrollment Status: Terminated
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: SLC-0111, Gemcitabine
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

143 Total Publications

An asynchronous electronic consent for improving consent in research among patients with cancer.
An asynchronous electronic consent for improving consent in research among patients with cancer.
Journal: The oncologist
Published: July 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Loree's expertise for a condition
ConditionClose
View All 10 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile